Aska Pharmaceutical Holdings Co., Ltd. (4886) Press Release
Summary of Consolidated Financial Results for the First Quarter of FY2026
Earlier from Aska Pharmaceutical
- Notice Concerning Disposal of Treasury Shares as Remuneration for Restricted Stock
- Notice Regarding Results of the 5th Ordinary General Meeting of Shareholders
- ASKA Pharmaceutical: May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area
- ASKA Pharmaceutical: April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries